Related content

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 3, 2016-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rationale and design of the long‐Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post–myocardial infarction patients (TIGRIS) study

By  

Clinical Cardiology, Vol. 40, Iss. 12, 2017-12 ,pp. : 1197-1204

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness analysis of 64-slice computed tomography vs. cardiac catheterization to rule out coronary artery disease before non-coronary cardiovascular surgery

By Catalán Paz   Callejo Daniel   Blasco Juan Antonio  

European Heart Journal Cardiovascular Imaging, Vol. 14, Iss. 2, 2013-02 ,pp. : 149-157

Oxford University Press

Access to resources Recommend Favorite

Percutaneous coronary interventions: benefit, risk and cost–effectiveness

By Dieter Robert S   Nanjundappa Aravinda  

Future Cardiology, Vol. 3, Iss. 3, 2007-05 ,pp. : 233-234

Future Medicine

Access to resources Recommend Favorite

Inflammatory response to percutaneous coronary intervention in stable coronary artery disease

By Munk Peter   Breland Unni   Aukrust Pål   Skadberg Oyvind   Ueland Thor   Larsen Alf  

Journal of Thrombosis and Thrombolysis, Vol. 31, Iss. 1, 2011-01 ,pp. : 92-98

Springer Publishing Company

Access to resources Recommend Favorite